Organogenesis Holdings Inc. Class A Common Stock (ORGO) is a publicly traded Healthcare sector company. As of May 21, 2026, ORGO trades at $2.55 with a market cap of $319.11M and a P/E ratio of 15.59. ORGO moved +5.35% today. Year to date, ORGO is -42.18%; over the trailing twelve months it is -21.78%. Its 52-week range spans $2.04 to $7.08. Analyst consensus is neutral with an average price target of $0.00. Rallies surfaces ORGO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Organogenesis Q1 Revenue Falls 58% to $36.3M, Loss Widens to $53.2M: Organogenesis reported Q1 net revenue of $36.3 million, down 58% from $86.7 million a year earlier, driven by a 63% drop in Advanced Wound Care sales to $29.5 million. The company posted a Q1 loss of $53.2 million, a $43.7 million adjusted net loss and $48.2 million adjusted EBITDA loss.
| Metric | Value |
|---|---|
| Price | $2.55 |
| Market Cap | $319.11M |
| P/E Ratio | 15.59 |
| EPS | $0.16 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.08 |
| 52-Week Low | $2.04 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $564.17M |
| Net Income | $37.03M |
| Gross Margin | 0.00% |
1 analysts cover ORGO: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $0.00.